New Drug for Lung Disease Clinical Success Leads to Large-Scale Executive Option Exercise

Insmed Inc. (NASDAQ: INSM) announced on March 23 that its inhaled antibiotic ARIKAYCE achieved the primary endpoint of a statistically significant improvement in respiratory symptom scores in the Phase 3b ENCORE post-marketing study of treatment-naive patients with Mycobacterium avium complex (MAC) lung disease. The company also confirmed faster and more sustained culture-negativity effects alongside the established safety profile. Based on these results, Insmed plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration in the second half of 2026 to convert ARIKAYCE’s conditional approval into full approval, and to file the data with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to expand the indication in both the U.S. and Japan from the roughly 30,000 refractory MAC patients currently covered to an additional 200,000 MAC lung disease patients.

On March 30, Chief Legal Officer Michael Alexander Smith exercised stock options to acquire about 19,000 common shares and sold them on the open market at approximately $151 per share under a pre-established Rule 10b5-1 trading plan, generating roughly $3 million (approximately ₩4 billion) in proceeds. On April 1, Chief Operating Officer Roger Adsett exercised approximately 88,000 stock options and sold all shares the same day at $163–165 each, yet retained about 195,000 shares, giving him an estimated post-transaction holding value of around $32 million (about ₩43 billion).

Following the release of the ENCORE Phase 3b top-line results, Insmed’s share price climbed 6–7% intraday on the U.S. stock market. International media outlets and several analysts have highlighted the potential market expansion arising from the anticipated broadened indication for ARIKAYCE. Insmed is also advancing its respiratory pipeline: its bronchiectasis candidate brensocatib will have its Phase 3 ASPEN study results published in the 2025 New England Journal of Medicine, and additional subgroup analyses will be presented at the 2025 American Thoracic Society International Conference.

Headquartered in New Jersey, Insmed is a biopharmaceutical company focused on developing and commercializing inhaled antibiotics and targeted therapies for patients with severe and rare lung diseases, including MAC lung disease. Its first commercial product, ARIKAYCE, is marketed in the U.S., Europe and Japan. With the global prevalence of nontuberculous mycobacterial lung infections and bronchiectasis on the rise, demand for these therapies is growing—and ARIKAYCE and brensocatib are Insmed’s core assets as it pursues further approvals and commercialization in this expanding market.